1. 0.0-AML-Home
2. 1.0-Efficacy-OS
3. 1.1-Efficacy-CR_CRh
4. 1.2-Hematologic-parameters
5. 1.3-Transfusion-independence
6. 1.4-EFS
7. 1.5-Safety
8. 10.0-Safety
9. 11.0-Dosing
10. 12.0-IDH1-mutations
11. 12.1-MOA
12. 13.0-GUIDELINES
13. 14.0-MDS_AML
14. 14.1-AML-genetic-abnormalities
15. 15.0-MDS-INDICATION-SUMMARY
16. 2.0-Efficacy-CR_CRh
17. 2.1-Duration-of-response
18. 2.2-Time-to-response
19. 2.3-Hematologic-parameters
20. 2.4-Transfusion-independence
21. 2.5-Safety
22. 3.0-Efficacy-CR-and_or-CRh
23. 3.1-Duration-of-response
24. 3.2-Time-to-response
25. 3.3-Transfusion-independence
26. 3.4-OS
27. 3.5-Hematologic-parameters
28. 3.6-Safety
29. 4.0-Dosing-regimen
30. 4.1-Dosing-guidance
31. 5.0-mIDH1
32. 5.1-Testing
33. 5.2-MoA
34. 6.0-GUIDELINES
35. 7.0-INDICATIONS-SUMMARY
36. 8.0-MDS-Home
37. 9.0-Unmet-need
38. 9.1-Remission
39. 9.2-Transfusion-independence
40. 9.3-Time-to-response
41. 9.4-Overall-survival
42. shared